JP2020507775A - 喘息またはアレルギー疾患迅速診断用キット - Google Patents
喘息またはアレルギー疾患迅速診断用キット Download PDFInfo
- Publication number
- JP2020507775A JP2020507775A JP2019543793A JP2019543793A JP2020507775A JP 2020507775 A JP2020507775 A JP 2020507775A JP 2019543793 A JP2019543793 A JP 2019543793A JP 2019543793 A JP2019543793 A JP 2019543793A JP 2020507775 A JP2020507775 A JP 2020507775A
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- asthma
- kit
- reaction
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 65
- 208000026935 allergic disease Diseases 0.000 title claims description 39
- 238000003745 diagnosis Methods 0.000 title claims description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 71
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 27
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 17
- 239000010931 gold Substances 0.000 claims description 16
- 229910052737 gold Inorganic materials 0.000 claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 claims description 12
- 230000007815 allergy Effects 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 23
- 238000011160 research Methods 0.000 abstract description 10
- 238000010586 diagram Methods 0.000 abstract 1
- 102000013888 Eosinophil-Derived Neurotoxin Human genes 0.000 description 35
- 108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000057955 Eosinophil Cationic Human genes 0.000 description 9
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 9
- 239000010408 film Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000003979 eosinophil Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- -1 gold ions Chemical class 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
ECP)などがこれにあたる。これらは、正常人、その他のアレルギー疾患、喘息などで全て個人的な差が大きいと知られており、診断に利用することはできない。
フロイントの完全アジュバント(Freund’s complete adjuvant)に溶解させた天然EDN抗原50〜100マイクログラムを雌BALB/cマウス(6〜8週齢)に静脈注射した。PBSまたは不完全アジュバントに溶解させたEDN抗原50〜100マイクログラムを2週〜3週間隔で注射した。EDN抗原を最終注射した後、抗体形成をマウス目における出血で確認した。抗体形成が一旦確認されれば、100〜200マイクログラムの抗体を3日〜4日連続的に注入した。マウスを切開し、70%アルコールに入れて滅菌した。脾臓を除去し、脾臓細胞を洗浄した後、円心分離して得て無血清培地に懸濁させた。
実施例のハイブリドーマ細胞株を組織培養フラスコで培養して単一クローン抗体を生産した。具体的に、75cm2組織培養フラスコでDMEM(Gibco BRL、U.S.A.)25mlに5×106個の細胞を添加した後、37細胞培養機で4〜5日間過多増殖させた後、細胞培養液を収去した。収去された細胞培養液は、1500rpmで15分間円心分離を実施して細胞成分を除去し、細胞上層液のみを回収することで単一クローン抗体生産を完了した。生産された単一クローン抗体は、試験に使うまで4℃または−20℃で保管した。
前記単一クローン抗体の製造時に金コロイドを結合させないことを除いては、同一の方法で製造した。
上記実施例2で製造した金粒子と単一クローン抗体が結合された金接合体をストリップ1個当り8.3マイクロリットル/ストリップを混合し、ポリエステル繊維またはガラス繊維に濡らして乾燥させ、第1反応部を含む結合パッドを製造した。
喘息またはアレルギー診断のために既存に使用された総好酸球数(total eosinophil count’ TEC)やECP(eosinophil cationic protein)に比べて本発明で喘息またはアレルギー診断に使用するEDNが優れることを立証するために、喘息またはアレルギー症状点数とELISA法で測定したEDN、ECP、及び総好酸球数を比べた。その結果、図2のように、EDNがTECやECPに比べて、各喘息またはアレルギー症状点数の重症度別差異を最もよく反映した。従って、EDNが喘息またはアレルギー診断時に有用な抗原として使用可能なことを確認した。
喘息またはアレルギーとして診断された5歳の幼児でEDN濃度が0.62ng/ml以上の血清80個検体、そして同一年齢で喘息またはアレルギーのない正常の血清50個検体を求め、本発明の診断キットとELISA法で検査した。図3のように、本発明の診断キットとELISA法による検査時に相関関係がr=0.603、P<0.001と優れて表れたことで、本発明の診断キットが迅速診断キットとして使用するのに十分な結果を表した。
実験例2と同一検体に対して、本発明の診断キット(Rapid)と、従来の喘息及びアレルギー診断キットとして知られたMBL(MEDICAL&BIOLOGICAL LABORATORIES CO.,LTD)キット、BFキットについて比較検査した。図4及び図5のように、本発明の診断キットとMBLキット、BFキットによる検査時に相関関係がそれぞれr=0.8933、r=0.8748と優れて表れることで、本発明の診断キットが迅速診断キットとして使用するのに十分な結果を表した。
寄託機関名:韓国細胞株研究財団(KCLRF)
寄託番号:KCLRF−BP−00389
寄託日付:2017年1月9日
Claims (8)
- 基底部と、
前記基底部上に位置し、ハイブリドーマ細胞株(寄託番号KCLRF−BP−00389)から発現される単一クローン抗体を含む第1反応部と、
前記第1反応部と前記基底部との間に位置し、ハイブリドーマ細胞株(寄託番号KCLRF−BP−00389)から発現される単一クローン抗体を含む第2反応部を含む展開膜と、を含むストリップを含む、喘息診断用キット。 - 前記単一クローン抗体は、金、HRP(horseradish peroxidase)、アルカリフォスファターゼ(alkaline phosphtase)、蛍光物質(fluorescein)及び色素からなる群より選択された1種以上のマーカーが結合されたものである、請求項1に記載の喘息診断用キット。
- 前記展開膜は、抗マウス免疫グロブリン(IgG)抗体を含む対照部をさらに含むものである、請求項1に記載の喘息診断用キット。
- 前記喘息診断用キットは、第2反応部の発色が表れれば喘息として診断するものである、請求項1に記載の喘息診断用キット。
- 基底部と、
前記基底部上に位置し、ハイブリドーマ細胞株(寄託番号KCLRF−BP−00389)から発現される単一クローン抗体を含む第1反応部と、
前記第1反応部と前記基底部との間に位置し、ハイブリドーマ細胞株(寄託番号KCLRF−BP−00389)から発現される単一クローン抗体を含む第2反応部を含む展開膜と、を含むストリップを含む、アレルギー疾患診断用キット。 - 前記単一クローン抗体は、金、HRP(horseradish peroxidase)、アルカリフォスファターゼ(alkaline phosphtase)、蛍光物質(fluorescein)及び色素からなる群より選択された1種以上のマーカーが結合されたものである、請求項5に記載のアレルギー疾患診断用キット。
- 前記展開膜は、抗マウス免疫グロブリン(IgG)抗体を含む対照部をさらに含むものである、請求項5に記載のアレルギー疾患診断用キット。
- 前記アレルギー疾患診断用キットは、第2反応部の発色が表れればアレルギーとして診断するものである、請求項5に記載のアレルギー疾患診断用キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0018517 | 2017-02-10 | ||
KR1020170018517A KR20180093179A (ko) | 2017-02-10 | 2017-02-10 | 천식 또는 알레르기 질환 신속 진단용 키트 |
PCT/KR2018/001757 WO2018147679A1 (ko) | 2017-02-10 | 2018-02-09 | 천식 또는 알레르기 질환 신속 진단용 키트 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020507775A true JP2020507775A (ja) | 2020-03-12 |
JP6807615B2 JP6807615B2 (ja) | 2021-01-06 |
Family
ID=63107781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019543793A Active JP6807615B2 (ja) | 2017-02-10 | 2018-02-09 | 喘息またはアレルギー疾患迅速診断用キット |
Country Status (5)
Country | Link |
---|---|
US (1) | US11009506B2 (ja) |
JP (1) | JP6807615B2 (ja) |
KR (1) | KR20180093179A (ja) |
CN (1) | CN110352352B (ja) |
WO (1) | WO2018147679A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110361546A (zh) * | 2019-08-28 | 2019-10-22 | 重庆三峡医药高等专科学校 | 一种检测嗜酸性粒细胞阳离子蛋白的胶体金试纸条 |
CN110376389A (zh) * | 2019-08-28 | 2019-10-25 | 重庆三峡医药高等专科学校 | 一种检测嗜酸性粒细胞碱性蛋白的胶体金试纸条 |
CN110361545A (zh) * | 2019-08-28 | 2019-10-22 | 重庆三峡医药高等专科学校 | 一种检测嗜酸性粒细胞源性神经毒素的胶体金试纸条 |
KR20210077476A (ko) | 2019-12-17 | 2021-06-25 | 엘지디스플레이 주식회사 | 발광 표시 장치 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002340897A (ja) * | 2001-05-14 | 2002-11-27 | Iatron Lab Inc | 複数項目及び総含有量の同時分析可能なイムノクロマトグラフ法及びイムノクロマトグラフ用ストリップ |
KR20030015017A (ko) * | 2001-08-14 | 2003-02-20 | 주식회사 코비아스 | 돼지 로타바이러스에 대한 단일클론 항체, 이를 생산하는하이브리도마 세포주, 이를 이용한 면역 측정 방법 및측정용 킷트 |
JP2012189355A (ja) * | 2011-03-09 | 2012-10-04 | Furukawa Electric Co Ltd:The | ラテラルフロー用テストストリップ |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928883A (en) * | 1996-11-13 | 1999-07-27 | Mayo Foundation For Medical Education | Eosinophil granole proteins as indicators of inflammatory bowel disorders |
AU777995B2 (en) * | 1999-03-16 | 2004-11-11 | University Of Florida Research Foundation, Inc. | Rapid diagnostic method for distinguishing allergies and infections |
US7288383B2 (en) * | 2003-01-15 | 2007-10-30 | The Brigham And Women's Hospital, Inc. | Eosinophil-derived neurotoxin as a marker for ovarian cancer |
CN103336121B (zh) * | 2013-06-13 | 2015-03-04 | 华中农业大学 | 猪流感病毒h3亚型胶体金检测试剂盒及其制备方法 |
KR20150145986A (ko) * | 2014-06-20 | 2015-12-31 | 연세대학교 산학협력단 | 안과 질환 진단 키트 |
KR101611743B1 (ko) * | 2014-10-28 | 2016-04-11 | 인제대학교 산학협력단 | 모세기관지염 후 천식 진단을 위한 마커 및 이의 용도 |
-
2017
- 2017-02-10 KR KR1020170018517A patent/KR20180093179A/ko active Search and Examination
-
2018
- 2018-02-09 JP JP2019543793A patent/JP6807615B2/ja active Active
- 2018-02-09 CN CN201880011507.3A patent/CN110352352B/zh active Active
- 2018-02-09 WO PCT/KR2018/001757 patent/WO2018147679A1/ko active Application Filing
- 2018-02-09 US US16/485,024 patent/US11009506B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002340897A (ja) * | 2001-05-14 | 2002-11-27 | Iatron Lab Inc | 複数項目及び総含有量の同時分析可能なイムノクロマトグラフ法及びイムノクロマトグラフ用ストリップ |
KR20030015017A (ko) * | 2001-08-14 | 2003-02-20 | 주식회사 코비아스 | 돼지 로타바이러스에 대한 단일클론 항체, 이를 생산하는하이브리도마 세포주, 이를 이용한 면역 측정 방법 및측정용 킷트 |
JP2012189355A (ja) * | 2011-03-09 | 2012-10-04 | Furukawa Electric Co Ltd:The | ラテラルフロー用テストストリップ |
Non-Patent Citations (3)
Title |
---|
CHANG-KEUN KIM ET AL.: "Utility of serum eosinophil-derived neurotoxin(EDN) measurement by ELISA in young children with asth", ALLERGOLOGY INTERNATIONAL, vol. 66, JPN6020042609, 2017, pages 70 - 74, XP055534503, ISSN: 0004382957, DOI: 10.1016/j.alit.2016.05.008 * |
GERD RUNDSTROM ET AL.: "Lateral Flow Immunoassay Using Europium(III) Chelate Microparticles and Time-Resolved Florescence fo", CLINICAL CHEMISTRY, vol. 53, JPN6020042614, 2007, pages 342 - 348, XP055460839, ISSN: 0004382959, DOI: 10.1373/clinchem.2006.074021 * |
J MORIOKA ET AL.: "Development of a novel enzyme-linked immunosorbent assay for blood and urinary eosinophil-derived ne", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 122, JPN6020042612, 2000, pages 49 - 57, ISSN: 0004382958 * |
Also Published As
Publication number | Publication date |
---|---|
CN110352352B (zh) | 2023-07-11 |
CN110352352A (zh) | 2019-10-18 |
US11009506B2 (en) | 2021-05-18 |
KR20180093179A (ko) | 2018-08-21 |
US20200041506A1 (en) | 2020-02-06 |
WO2018147679A1 (ko) | 2018-08-16 |
JP6807615B2 (ja) | 2021-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7260192B2 (ja) | マイコプラズマ・ニューモニエの免疫学的検出法およびキット | |
JP6807615B2 (ja) | 喘息またはアレルギー疾患迅速診断用キット | |
JP5963900B2 (ja) | オートタキシン測定による悪性リンパ腫の検査方法および検査薬 | |
JP5852657B2 (ja) | イムノクロマトグラフィー装置、方法およびキット | |
JP7524237B2 (ja) | マイコプラズマ・ニューモニエの免疫学的検出法及びキット | |
JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
CN111487419B (zh) | Kl-6在儿童新冠肺炎中的应用 | |
CN113248609B (zh) | 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒 | |
CN111018971B (zh) | 柯萨奇病毒a6型实心病毒的单克隆抗体及其应用 | |
EP1913395A2 (en) | Antibodies and methods for predicting dental caries | |
CN110938140A (zh) | 柯萨奇病毒a10型实心病毒的单克隆抗体及其应用 | |
JP6027744B2 (ja) | ヒトインスリン測定方法及び測定試薬 | |
CN117777287B (zh) | 靶向降钙素原的抗体f4b4及其应用 | |
JP2020526745A (ja) | 血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法 | |
JP5798679B2 (ja) | ヒト肝−カルボキシルエステラーゼ1を特異的に認識するモノクローナル抗体、前記抗体を生産するハイブリドーマ細胞株及びその用途 | |
EP4386385A1 (en) | Immunoassay method, specimen diluent, and immunochromatography kit | |
WO2023277143A1 (ja) | SARS-CoV-2のヌクレオカプシドタンパク質に対する抗体及びその用途 | |
CN117777286A (zh) | 靶向降钙素原的抗体a4d7及其应用 | |
JP2020204554A (ja) | 軽度認知障害の診断マーカー | |
CN117683121B (zh) | 抗水痘-带状疱疹病毒抗体及其应用 | |
CN117024586B (zh) | 一种抗体组合物及应用于检测血液中ykl-40浓度的方法 | |
KR102676458B1 (ko) | 보툴리눔 독소 a에 특이적인 항체, 이를 생산하는 하이브리도마 세포주, 및 이를 이용한 보툴리눔 독소 a 진단 키트 | |
CN115975025A (zh) | C反应蛋白(crp)检测试剂盒 | |
EP3653646A1 (en) | Method and kit for the diagnosis and/or prognosis of inflammatory conditions | |
WO2014073653A1 (ja) | 腎炎の病変部位の検査方法およびそのための試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191218 |
|
TRDD | Decision of grant or rejection written | ||
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201030 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6807615 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |